According to the American Heart Association, more people die from heart attacks during the last week of December than at any other time of the year.

With new phase 3 data backing the ability of its emergency use zalunfiban to fend off further heart damage, CeleCor Therapeutics is one step closer to bringing a speedy new weapon to the race against ...